A PHASE I TRIAL OF IMMUNOSUPPRESSION WITH ANTIIC AM-1 (CD54) mAb IN RENAL ALLOGRAFT RECIPIENTS
CRAIG E. HAUG(Massachusetts General Hospital), A. Benedict Cosimi(Massachusetts General Hospital), Hugh Auchincloss(Massachusetts General Hospital), Robert Rothlein(Thomas Jefferson University), Linda A. Scharschmidt(Boehringer Ingelheim (United States)), Nina Tolkoff-Rubin(Harvard University), FREDERIC I. PREFFER, F L Delmonico(Harvard University), Robert B. Colvin(Harvard University)
Cited by 300
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
|Kidney International|1993|1.5k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k